NEW YORK (GenomeWeb News) – Invitrogen announced today that it will work with Maryland-based biotechnology company Lentigen to develop and market products and services for gene over-expression based on Lentigen’s lentiviral gene delivery technology and Invitrogen’s human gene collections and cloning and gene synthesis technologies.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.